Optic Nerve Disorders and Papilledema

Raised-ICP mechanisms (true papilledema, always consider first)

• Space-occupying lesions: tumor, abscess, or hemorrhage producing mass effect; posterior fossa lesions cause obstructive hydrocephalus
• Impaired CSF outflow: cerebral venous sinus thrombosis, meningitis/subarachnoid hemorrhage (arachnoid granulation scarring), aqueductal stenosis
• Idiopathic intracranial hypertension (IIH): elevated pressure with normal imaging and normal CSF composition
• Malignant hypertension: disc swelling with flame hemorrhages and macular star exudates

Non-ICP optic neuropathies by mechanism

• Inflammatory/demyelinating: MS-associated optic neuritis; NMOSD (aquaporin-4 IgG, severe bilateral or chiasmal disease) and MOG antibody disease (marked disc edema, steroid-responsive)
• Ischemic: arteritic AION from giant cell arteritis (vasculitic occlusion of posterior ciliary arteries) versus non-arteritic AION (small crowded disc at risk, nocturnal hypotension)
• Compressive/infiltrative: optic nerve sheath meningioma, glioma, pituitary macroadenoma, thyroid eye disease at the orbital apex, lymphoma or carcinomatous infiltration
• Toxic/nutritional: ethambutol, methanol, amiodarone, B12/folate/thiamine deficiency — characteristically bilateral, painless, with early color desaturation
• Hereditary: Leber hereditary optic neuropathy (mitochondrial, maternally inherited, males disproportionately affected)

Modifiable risk factors examiners plant

• Obesity and recent weight gain: the dominant driver in IIH; weight loss is disease-modifying
• Drugs: tetracyclines (doxycycline, minocycline), excess vitamin A/isotretinoin, growth hormone, and corticosteroid withdrawal all precipitate IIH
• Vascular risk factors: hypertension, diabetes, dyslipidemia, obstructive sleep apnea, and nocturnal hypotension (including evening antihypertensive dosing) favor non-arteritic AION
• Smoking: worsens thyroid eye disease and converts LHON carriers to symptomatic disease
• Uncontrolled intraocular pressure: the only modifiable factor in glaucomatous optic neuropathy

Non-modifiable

• Female sex of reproductive age for IIH; age over 50 with Northern European ancestry for giant cell arteritis (per ACR classification criteria, GCA is not diagnosed under age 50)
• Congenitally small, crowded optic disc for NAION; hypermetropia; family history of glaucoma and African ancestry for open-angle glaucoma

Papilledema Mechanism

• Axoplasmic flow obstruction: Elevated ICP compresses the optic nerve at the optic disc, impeding anterograde and retrograde axoplasmic transport in retinal ganglion cell axons
• Axonal swelling and disc edema: Accumulation of neurofilaments, mitochondria, and cellular organelles causes optic disc swelling that progresses from the nasal margin (most sensitive to pressure) to the temporal margin
• Progressive structural changes: Early papilledema shows blurred nasal disc margins; chronic papilledema leads to Paton's lines (circumferential retinal folds), obscuration of vessels, disc hyperemia, and eventual optic atrophy with vision loss

Other Optic Nerve Disorders

• Optic neuritis (demyelinating): Inflammation of the optic nerve (often associated with multiple sclerosis), causing demyelination and axonal injury with relative afferent pupillary defect (RAPD) and central scotoma
• Ischemic optic neuropathy: Vascular insufficiency causing sudden, painless vision loss; anterior ischemic optic neuropathy (AION) from arteritic or non-arteritic causes affects the optic nerve head; posterior ischemic optic neuropathy affects the retrobulbar nerve
• Glaucomatous optic neuropathy: Mechanical compression and ischemia from intraocular pressure elevation causing cupping and progressive nerve fiber layer loss
• Hereditary/toxic optic neuropathies: Mitochondrial dysfunction (Leber hereditary optic neuropathy), nutritional deficiency (B12, folate), or toxins (ethambutol, methanol) causing bilateral optic nerve damage
• Compressive lesions: Tumors, aneurysms, or inflammatory masses causing optic nerve compression with gradual vision loss and possible RAPD

Papilledema

• Early stage: Asymptomatic disc swelling; blurring of nasal optic disc margin; normal visual acuity and visual fields initially (key distinguishing feature from other optic neuropathies)
• Progressive papilledema: Increasing disc edema, obliteration of cup, vessel obscuration at disc edges, hyperemia, hemorrhages at disc margin, cotton-wool spots, and Paton's lines (circumferential retinal folds from chronic elevated ICP)
• Chronic/atrophic stage: Optic atrophy with gliosis, leading to gradual visual field constriction (peripheral initially, then progressive), enlargement of blind spot, and potential permanent vision loss if untreated
• Symptoms: Late-stage patients report transient visual obscurations (TVOs)—brief episodes of dimming vision lasting seconds (caused by brief ICP surges); headache and neurologic symptoms from underlying cause (tumor, infection, hemorrhage)

Optic Neuritis

• Subacute painful vision loss: Pain with eye movements (retrobulbar inflammation); visual loss over hours to days; central scotoma on formal visual field testing
• RAPD present (distinguishes from papilledema and most other causes)
• Disc appearance variable: Can range from normal (retrobulbar) to mild disc swelling; typically less swelling than papilledema
• Age and demographics: Young adults (20-40 years); female predominance; high association with MS (demyelinating disease)

Anterior Ischemic Optic Neuropathy (AION)

• Sudden, painless vision loss with altitudinal (wedge-shaped) visual field defect—hallmark finding
• Disc edema with pallor and nerve fiber layer infarction
• Arteritic AION: Older patients (>50 years) with giant cell arteritis (GCA); systemic symptoms (fever, malaise, jaw claudication, temporal headache); elevated ESR and CRP
• Non-arteritic AION: Smaller optic disc cups; hypertension, diabetes, or other vascular risk factors; more common form

Glaucomatous Optic Neuropathy

• Asymptomatic early stages with gradual optic cup enlargement and vertical cup-to-disc ratio >0.5 or asymmetry between eyes
• Progressive visual field loss in glaucoma pattern (nasal step, arcuate defects, peripheral constriction) detected on perimetry
• Nerve fiber layer thinning on optical coherence tomography (OCT)

Compressive Optic Neuropathy

• Gradual vision loss and color vision defects (dyschromatopsia, particularly red desaturation)
• RAPD if unilateral compression
• Possible prism diplopia if mass affects extraocular muscles
• Afferent visual field defects (may be central scotoma, arcuate, or other patterns depending on mass location)

Key Clinical Pearls

• Normal visual acuity with disc swelling = papilledema until proven otherwise; other optic neuropathies typically cause vision loss
• RAPD indicates optic nerve pathology and is absent in papilledema alone (unless asymmetric); present in optic neuritis and unilateral compression
• Fundoscopic findings lag behind ICP elevation: Papilledema may be absent despite dangerously elevated ICP in acute increases

Papilledema Diagnosis

• Clinical fundoscopy: Blurred disc margins (nasal >temporal), loss of spontaneous venous pulsations (though absent in ~20% of normal individuals), disc hyperemia, vessels obscured at disc, hemorrhages, Paton's lines, and exudates (especially macular "macular star" exudates arranged in a star pattern)
• Optical coherence tomography (OCT) of optic nerve head: Quantifies disc swelling; elevated retinal nerve fiber layer (RNFL) thickness and obscuration of disc margins; useful for staging and monitoring progression
• Fundus photography: Serial documentation of disc appearance to track progression or resolution
• Visual fields (perimetry): Early papilledema: enlarged blind spot; progressive papilledema: peripheral constriction; confirms functional impact
• Neuroimaging (MRI with contrast or CT): Identifies underlying cause of elevated ICP (tumor, hemorrhage, venous sinus thrombosis, idiopathic intracranial hypertension); also assess for empty sella or increased optic nerve sheath diameter
• Lumbar puncture (if imaging negative): Measured opening pressure >25 cm H₂O (normal <25 cm H₂O in lateral recumbent position); cerebrospinal fluid (CSF) analysis to rule out infection or malignancy

Optic Neuritis Diagnosis

• Clinical presentation: Subacute vision loss with pain and RAPD in a young adult
• MRI brain and orbit with contrast: Hyperintense lesion in optic nerve on T2/FLAIR sequences; helps confirm demyelination; assess for brain white matter lesions (suggestive of MS)
• Visual evoked potentials (VEPs): Prolonged latency and reduced amplitude indicating demyelination and slowed conduction velocity; useful if MRI inconclusive
• Differential: Distinguish from posterior ischemic optic neuropathy (painless, older patients, vascular risk factors) and compressive lesions (imaging findings)

AION Diagnosis

• Fundoscopy: Sector or diffuse disc swelling with pallor; nerve fiber layer infarction; altitudinal visual field defect on perimetry (horizontal division at midline)
• Arteritic AION workup: Temporal artery biopsy (gold standard); **elevated ESR (>50 mm/hr) and

Immediate stabilization

• Treat the ICP source before the disc: obtain neuroimaging first; in a mass lesion or obstructive hydrocephalus, lumbar puncture risks herniation. Neurosurgical decompression, CSF diversion, or head-of-bed elevation with osmotic therapy (mannitol or hypertonic saline) precedes any ophthalmic measure
• Suspected giant cell arteritis is a same-day emergency: start high-dose systemic corticosteroids (IV methylprednisolone for vision loss, otherwise oral prednisone) before temporal artery biopsy — the ACR/EULAR guideline states biopsy yield remains adequate for roughly two weeks after steroids are begun. Tocilizumab is the guideline-endorsed steroid-sparing agent

First-line therapy by diagnosis

• IIH: carbonic anhydrase inhibitor — acetazolamide — reduces CSF production; combined with structured weight loss this improved visual fields in the NIH-sponsored Idiopathic Intracranial Hypertension Treatment Trial. Stop the offending drug (tetracycline, retinoid)
• Optic neuritis: IV corticosteroid — methylprednisolone followed by an oral taper, per the Optic Neuritis Treatment Trial — hastens recovery but does not change final visual acuity
• Glaucomatous optic neuropathy: prostaglandin analog — latanoprost — first-line topical pressure lowering per the AAO Preferred Practice Pattern

Escalation and second-line

• Topiramate as an alternative in IIH (weak carbonic anhydrase activity plus appetite suppression); furosemide as an adjunct
• Plasma exchange for steroid-refractory or NMOSD-related optic neuritis; long-term relapse prevention in AQP4-positive disease uses B-cell or complement-directed biologics (rituximab, eculizumab)

Definitive/surgical

• Fulminant IIH with progressive field loss: optic nerve sheath fenestration (protects the nerve) or CSF shunting (treats headache and pressure); venous sinus stenting where a pressure-gradient stenosis is documented
• Bariatric surgery for sustained weight reduction in refractory IIH

Contraindicated/avoid

• Oral prednisone alone for optic neuritis — ONTT showed a higher recurrence rate
• LP before imaging with focal deficits or papilledema of unknown cause
• Corticosteroids or aspirin as treatment for established NAION — no proven benefit; PDE5 inhibitors and evening antihypertensives should be reconsidered
• Acetazolamide caution in sulfonamide hypersensitivity, cirrhosis, and significant renal impairment

Of the disease

• Secondary optic atrophy from chronic papilledema: sustained axoplasmic stasis kills ganglion cell axons; the disc becomes pale with gliosis and the swelling paradoxically "improves" while fields constrict. Signaled by progressive peripheral constriction, loss of color vision, and a falling RNFL on OCT
• Fulminant IIH: rapid field loss over days — an emergency requiring urgent surgical decompression, not outpatient titration of acetazolamide
• Cerebral herniation after lumbar puncture in an undiagnosed mass lesion: an emergency; heralded by depressed consciousness, a blown pupil, or new posturing
• Fellow-eye involvement in arteritic AION: untreated GCA blinds the second eye within days to weeks — an emergency; GCA also carries stroke and thoracic aortic aneurysm risk
• Conversion to multiple sclerosis after optic neuritis: risk is driven by baseline brain white-matter lesions on MRI; in AQP4-positive NMOSD, attacks are more severe and bilateral
• Uhthoff phenomenon: transient blurring with heat or exercise, reflecting conduction block in demyelinated axons — a residual finding, not a relapse

Of treatment

• Acetazolamide: non–anion gap hyperchloremic metabolic acidosis with paresthesias and dysgeusia; hypokalemia and calcium phosphate nephrolithiasis; rarely aplastic anemia
• Topiramate: kidney stones, cognitive slowing, and acute angle-closure glaucoma with myopic shift; teratogenic (oral clefts) in a population that is largely reproductive-age women
• Systemic corticosteroids: hyperglycemia, osteoporosis and fracture, avascular necrosis, adrenal suppression on abrupt withdrawal; tocilizumab masks the CRP/ESR response and carries GI perforation risk
• CSF shunting: obstruction (recurrent papilledema), infection, and low-pressure orthostatic headache
• Optic nerve sheath fenestration: diplopia from extraocular muscle injury, and rarely central retinal artery occlusion
• Topical glaucoma agents: prostaglandin analogs cause iris and periocular hyperpigmentation, lash growth, and periorbital fat atrophy; timolol can precipitate bronchospasm and bradycardia

• Papilledema is bilateral and spares acuity early: swelling in one eye with reduced acuity and an RAPD is optic neuritis, AION, or compression — not papilledema. Preserved acuity with an enlarged blind spot is the giveaway
• Imaging before lumbar puncture: the single best next step for new papilledema is MRI brain with MR venography (to exclude a mass and cerebral venous sinus thrombosis); only then measure opening pressure
• Obese young woman, headache, transient visual obscurations, pulsatile tinnitus, sixth nerve palsy: IIH. The sixth nerve palsy is a false localizing sign from CN VI's long intracranial course — do not read it as a brainstem lesion
• Age over 50 with jaw claudication, scalp tenderness, and a chalky-white swollen disc: give corticosteroids immediately; biopsy can wait, vision cannot. The classic distractor is delaying steroids pending ESR/CRP or biopsy
• Pain with eye movement plus central scotoma in a young woman: optic neuritis — IV methylprednisolone per ONTT shortens recovery but does not improve final acuity, and oral prednisone alone increases recurrence
• The association examiners love: Foster Kennedy syndrome — ipsilateral optic atrophy from direct compression plus contralateral papilledema from raised ICP, classically a frontal lobe or olfactory groove meningioma with anosmia
• Pseudopapilledema from optic disc drusen is the great mimic: no hyperemia, no hemorrhages, no obscured vessels, and autofluorescence or B-scan ultrasound shows calcification — avoid the reflex LP
• Toxic clues: ethambutol and B12 deficiency cause painless bilateral central scotomas with early red-green dyschromatopsia; methanol adds metabolic acidosis with an osmolar gap
• NAION versus arteritic AION: NAION occurs in a small crowded disc at risk with normal inflammatory markers and has no proven therapy — steroids and aspirin are distractors